Hospitals | March 31, 2022
Bronchoscopic Thermal Vapor Ablation (BTVA): A new ray of hope for COPD patients
Yashoda Hospitals Hyderabad has earned the distinction of becoming the first to introduce BTVA in India
Yashoda Hospitals Hyderabad has earned the distinction of becoming the first to introduce BTVA in India
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
The registry will be conducted for approximately two and a half years and up to 200 subjects will be enrolled
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults
In May 2021, Daiichi Sankyo had submitted a supplemental new drug application (sNDA) for Tarlige tablets based on results from a phase 3 trial in patients with CNP
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
Titan 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy
Spread over 43,000 square feet, the facility will be set up to cater to the increasing demand for transformative molecular testing in India and across the world for early and accurate diagnosis
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
